Verici Dx plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more
Verici Dx plc (VRCDF) - Net Assets
Latest net assets as of June 2025: $2.48 Million USD
Based on the latest financial reports, Verici Dx plc (VRCDF) has net assets worth $2.48 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.54 Million) and total liabilities ($2.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.48 Million |
| % of Total Assets | 54.61% |
| Annual Growth Rate | -28.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.54 |
Verici Dx plc - Net Assets Trend (2020–2024)
This chart illustrates how Verici Dx plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Verici Dx plc (2020–2024)
The table below shows the annual net assets of Verici Dx plc from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.26 Million | +47.98% |
| 2023-12-31 | $3.56 Million | -69.09% |
| 2022-12-31 | $11.51 Million | -3.97% |
| 2021-12-31 | $11.98 Million | -38.93% |
| 2020-12-31 | $19.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Verici Dx plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3434499300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $310.00K | 5.89% |
| Other Components | $44.03 Million | 836.37% |
| Total Equity | $5.26 Million | 100.00% |
Verici Dx plc Competitors by Market Cap
The table below lists competitors of Verici Dx plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mirae JSC
VN:KMR
|
$4.54 Million |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
$4.54 Million |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
$4.54 Million |
|
Tempest Security AB
ST:TSEC
|
$4.54 Million |
|
NSN Co. Ltd
KQ:031860
|
$4.54 Million |
|
Urteste SA
WAR:URT
|
$4.54 Million |
|
eEducation Albert AB
ST:ALBERT
|
$4.54 Million |
|
Tadiran Hldg
TA:TDRN
|
$4.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verici Dx plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,558,000 to 5,265,000, a change of 1,707,000 (48.0%).
- Net loss of 5,874,000 reduced equity.
- New share issuances of 8,196,000 increased equity.
- Other comprehensive income decreased equity by 3,593,918.
- Other factors increased equity by 2,978,918.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.87 Million | -111.57% |
| Share Issuances | $8.20 Million | +155.67% |
| Other Comprehensive Income | $-3.59 Million | -68.26% |
| Other Changes | $2.98 Million | +56.58% |
| Total Change | $- | 47.98% |
Book Value vs Market Value Analysis
This analysis compares Verici Dx plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.13x to 1.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.23 | $0.03 | x |
| 2021-12-31 | $0.08 | $0.03 | x |
| 2022-12-31 | $0.07 | $0.03 | x |
| 2023-12-31 | $0.02 | $0.03 | x |
| 2024-12-31 | $0.02 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verici Dx plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -175.92%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.42x
- Recent ROE (-111.57%) is below the historical average (-110.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -25.72% | 0.00% | 0.00x | 1.03x | $-7.01 Million |
| 2021 | -69.50% | 0.00% | 0.00x | 1.15x | $-9.53 Million |
| 2022 | -99.11% | 0.00% | 0.00x | 1.24x | $-12.56 Million |
| 2023 | -245.47% | -862.19% | 0.14x | 2.09x | $-9.09 Million |
| 2024 | -111.57% | -175.92% | 0.45x | 1.42x | $-6.40 Million |
Industry Comparison
This section compares Verici Dx plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verici Dx plc (VRCDF) | $2.48 Million | -25.72% | 0.83x | $4.54 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |